Yan WX, Yuan HQ, Xiong ZY, Qin LJ, Wu J, He J, Mu J, Li J, Li N. Meta-analysis of the efficacy of neoadjuvant immunotherapy combined with radiotherapy and chemotherapy for locally advanced rectal cancer. World J Gastrointest Oncol 2025; 17(11): 113048 [DOI: 10.4251/wjgo.v17.i11.113048]
Corresponding Author of This Article
Ning Li, Department of Radiation Oncology, Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University, No. 3 Zhigongxin Street, Taiyuan 030013, Shanxi Province, China. lee_ak@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nov 15, 2025 (publication date) through Nov 13, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Yan WX, Yuan HQ, Xiong ZY, Qin LJ, Wu J, He J, Mu J, Li J, Li N. Meta-analysis of the efficacy of neoadjuvant immunotherapy combined with radiotherapy and chemotherapy for locally advanced rectal cancer. World J Gastrointest Oncol 2025; 17(11): 113048 [DOI: 10.4251/wjgo.v17.i11.113048]
World J Gastrointest Oncol. Nov 15, 2025; 17(11): 113048 Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.113048
Meta-analysis of the efficacy of neoadjuvant immunotherapy combined with radiotherapy and chemotherapy for locally advanced rectal cancer
Wen-Xing Yan, Hong-Qin Yuan, Ze-Yi Xiong, Li-Juan Qin, Juan Wu, Juan He, Jie Mu, Jia Li, Ning Li
Wen-Xing Yan, Hong-Qin Yuan, Ze-Yi Xiong, Li-Juan Qin, Juan Wu, Juan He, Jie Mu, Jia Li, Ning Li, Department of Radiation Oncology, Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, Shanxi Province, China
Ning Li, Department of Radiation Oncology, Chinese Academy of Medical Sciences Cancer Hospital, Beijing 100000, China
Author contributions: Li N was responsible for conceptualization; Yuan HQ and Yan WX were responsible for data curation; Xiong ZY was responsible for formal analysis; Qin LJ and Li N were responsible for funding acquisition, investigation; Yan WX was responsible for methodology; He J was responsible for project administration; Wu J and He J were responsible for resources; Yan WX was responsible for software and supervision; Mu J and Yan WX were responsible for validation; Mu J and Yuan HQ were responsible for visualization; Yan WX was responsible for roles/writing - original draft; Li N was responsible for writing- review & editing; Li J was responsible for supervision.
Supported by Start-up Fund for Doctor's Scientific Research in Shanxi Cancer Hospital, No. Dr202314; and Natural Exploration Category of Shanxi Basic Research Plan, No. 202203021221284.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ning Li, Department of Radiation Oncology, Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University, No. 3 Zhigongxin Street, Taiyuan 030013, Shanxi Province, China. lee_ak@163.com
Received: August 14, 2025 Revised: September 9, 2025 Accepted: October 23, 2025 Published online: November 15, 2025 Processing time: 92 Days and 1.3 Hours
Core Tip
Core Tip: Immunotherapy is an approved treatment for metastatic rectal cancer in patients with defective mismatch repair (MMR). Neoadjuvant chemotherapy combined with immunotherapy can benefit patients who have locally advanced rectal cancer (LARC) with proficient MMR (pMMR)/microsatellite stability (MSS). Through a meta-analysis with 15 publications included, the results of our meta-analysis showed that neoadjuvant immunotherapy combined with radiotherapy and chemotherapy can improve the clinical remission rate (major pathologic response, clinical complete response, and pathologic complete response) of patients with LARC, especially for those with pMMR/MSS, and this treatment did not increase the incidence of postoperative complications and adverse reactions.
